AUROBINDO PHARMA LIMITED has announced the successful conclusion of a US FDA inspection at Unit-IV, an API manufacturing facility of its wholly-owned subsidiary, Apitoria Pharma Private Limited. The inspection, conducted from September 07 to September 11, 2026, resulted in zero observations, underscoring the company’s commitment to robust quality and compliance standards across its manufacturing operations.
US FDA Inspection Concludes Positively
AUROBINDO PHARMA LIMITED (AUROBINDO PHARMA) today announced the successful completion of an inspection conducted by the United States Food and Drug Administration (US FDA) at its subsidiary’s facility. The inspection targeted Unit-IV, a key Active Pharmaceutical Ingredient (API) manufacturing site operated by Apitoria Pharma Private Limited, a wholly-owned subsidiary of AUROBINDO PHARMA.
Inspection Details and Outcome
The US FDA inspection took place at the facility located in Industrial Development Area, Pydibhimavaram, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh. The inspection period spanned from September 07, 2026, to September 11, 2026. AUROBINDO PHARMA is pleased to report that the inspection concluded with zero observations. This outcome highlights the adherence to high-quality and compliance standards maintained by the company.
Commitment to Quality
AUROBINDO PHARMA reiterated its unwavering commitment to maintaining robust quality and compliance standards across all its manufacturing facilities. The company will continue to keep the stock exchanges informed of any further developments as required by applicable regulations.
Source: BSE
